Posts

Presentation: Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats (Abstract #160)

Propella Therapeutics, Inc. presented “Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats (Abstract #160)” at the American Society of Clinical Oncology Genitourinary Symposium on February 17, 2022.

Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event

Propella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer.

Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index

Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.

Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer

Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.